GlobeNewsWire
08 Dec 2025, 13:00 UTC · 40w ago
Verdict
Headline takes no side. We score NRIX +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Bexobrutideg achieved a 75.0% objective response rate (ORR) with deepening and durable responses in heavily pre-treated Waldenström macroglobulinemia patients.
So whatA 75% ORR with durable responses in a difficult-to-treat, heavily pre-treated population significantly de-risks the clinical program and supports best-in-class potential, directly boosting the asset's valuation.
More positive than 99% of claims this week
Bexobrutideg demonstrated a favorable safety profile in WM patients with no dose-limiting toxicities, no grade 5 adverse events, and no new onset atrial fibrillation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 96% of claims this week
Bexobrutideg is currently being evaluated in a pivotal single-arm Phase 2 study for relapsed or refractory CLL.
More positive than 91% of claims this week
Bexobrutideg elicited responses in WM patients regardless of baseline MYD88 and CXCR4 mutations, and showed early activity in patients with CNS involvement.
More positive than 84% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company reported positive Phase 1 clinical data for bexobrutideg, showing a 75% objective response rate and favorable tolerability.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
1d ago
+40.5%
Price agrees with the score
$25.41 vs $18.09 close before publication (Dec 5) · not market-adjusted
NRIX chart →
